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Radiotherapy (RT) can achieve good results in the treatment of non-small-cell lung cancer (NSCLC). The key is how to monitor the dose to critical normal tissues such as the heart, normal lung, and esophagus. Several factors can minimize the dose of RT to the esophagus, including proximity of the esophagus to midline tumors or mediastinal adenopathy, proximity of the esophagus to higher priority organs such as spinal cord and heart and relative paucity of information on the clinical and dosimetric predictors of radiation-induced esophageal injury.
Clinicians familiar with RT planning are often forced to evaluate multiple plans that produce equivalent coverage of the target with variable sparing of critical structures. By our experience, the esophageal dose is not critically considered because the clinical and dosimetric variables predicting esophageal injury are not well characterized. The purpose of this investigation was to analyze the incidence of acute and late grade 3-5 esophageal injury in patients with NSCLC during three-dimensional conformal radiotherapy (3D-CRT) combined with or without chemotherapy (sequential or concurrent).
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Patients
From October 2000 to June 2002, 208 consecutive patients (146 men and 62 women, average 67 years of age) with inoperable NSCLC completed the treatment of high-dose RT. Patients were considered inoperable on the basis of mediastinal lymph node involvement (N2 or N3), bulky primary disease (T3 or T4), and/or advanced disease states. All patients had biopsy-proven NSCLC. Patient characteristics and pathologic subtypes are shown in Table 1 . Patients with metastatic disease and those treated with palliative dose (<60 Gy) were not included in this study.
Initial evaluation
The initial evaluation was based on a complete history and physical examination, chest X-ray, CT of the chest through the liver and adrenal glands, and a bone scan. CT of the brain was obtained to evaluate any suspicious neurologic symptoms.
Treatment dose
All patients were treated with 1.8-2.0 Gy daily. The median dose to the isocenter was 70 Gy (range 60-72 Gy). Doses were reported without heterogenous corrections.
Chemotherapy
Ninety-eight (47%) patients received chemotherapy as a part of definitive treatment. Fifty-four patients received sequential chemotherapy (administered before initiation of RT). Fifty-four patients received concurrent chemotherapy (administered during RT). The chemotherapy records were available for 54 patients ( Table 2) , 43 of them were treated with concurrent cisplatin-based chemotherapy. None of the three patients treated with gemcitabine developed grade 3-5 esophageal injury. Two patients died (grade 5 esophageal injury) of perforation. No grade 3-5 esophageal injury was found in patients who received sequential chemotherapy of cisplatin and etoposide.
Evaluation during follow-up
During RT, patients were seen once a week or more as needed for evaluation and treatment of complaints. After completion of RT, patients were followed up at intervals of 2-3 mo for 2 years. Acute and late esophageal injuries were graded according to Radiation Therapy Oncology Group (RTOG) criteria (Table 3 ). The median follow-up period was 24 mo. The follow-up evaluations consisted of a history and physical examination.
Dosimetric analysis
Three-dimensional treatment was planned as previously described [1] . The esophagus was contoured from the thoracic inlet to the diaphragm. All patients had full treatment plans based on volumetric dose calculations. The doses prescribed and reported in this study were not corrected for tissue heterogeneity.
Statistical analysis
The following parameters were studied, including age, gender, performance status, sequential chemotherapy, concurrent chemotherapy, presence of subcarinal lymph nodes, mean dose to the entire esophagus, maximal esophageal point dose, pretreatment weight loss, and percentage of volume of esophagus receiving >55 Gy. Patients were defined as having acute esophageal injury according to RTOG criteria if the symptoms developed during treatment or within the first 3 mo after RT, while those were defined as having late esophageal injury if the symptoms persisted or occurred after 3 mo of follow-up. The patients and treatment/dosimetric factors were coded and correlated with acute and late grade 3-5 esophageal injury by univariate and multivariate regression analyses. Statistical analysis was performed using SPSS 10.0 for Windows.
RESUL RESUL RESUL RESUL RESULTS TS TS
TS TS Twenty-five (12%) of the two hundred and eight patients developed acute (14) or late (11) grade 3-5 esophageal injury. Nine patients developed both acute and late grade 3-5 esophageal injury. Two patients died of perforation (grade 5 esophageal injury). The incidence of acute and late esophageal injury is summarized in Table 4 .
Univariate analysis showed that concurrent chemotherapy, maximal point dose to the esophagus 60 Gy, subcarinal lymph nodes and mean esophageal dose 40 Gy were associated with the risk for grade 3-5 esophageal injury, whereas mean esophageal dose 40 Gy and subcarinal lymph nodes did not retain significance on multivariate analysis (Table 5) .
Among the 208 patients, 54 (26%) received concurrent chemotherapy, 23 (92%) of the 25 patients who developed grade 3-5 esophageal injury received concurrent chemotherapy (P = 0.0001<0.01). Sequential chemotherapy was not associated with the grade 3-5 esophageal injury. Grade 3-5 esophageal injury did not occur in patients who received a maximal dose to the esophagus <60 Gy (P = 0.0001<0.01). Only two patients who did not receive concurrent chemotherapy developed grade 3-5 esophageal injury. Severe dysphagia or odynophagia with dehydration or weight loss (>15% of pretreatment baseline), requiring nasogastric feeding 4
Complete stricture, ulceration, perforation or fistula 5 Death RTOG, Radiation Therapy Oncology Group. During the follow-up period, chest X-ray examination was performed at intervals of 2-3 mo. CT scan of the chest was carried out every 2-3 mo after treatment, or earlier if clinically indicated. Damage to the esophagus is a major limiting factor in RT of intrathoracic tumors. Radiation-induced esophagitis presents various symptoms such as mild substernal burning sensation, severe pain, odynophagia and dysphagia. Acute change occurs, about 2 wk after initiation of therapy, and is largely limited to the mucosa. Most changes that occur later than 3 mo or more after irradiation are mortal disturbances possibly due to damage to nerves and smooth muscle, stricture may eventually develop [2] . It was reported that abnormalities include abnormal mortality with or without mucosal edema, stricture, ulceration, pseudodiverticulum and fistula, abnormal death occurs 4-12 wk following RT alone and as early as 1 wk after therapy when concurrent chemotherapy is given, strictures often develop 4-8 mo following completion of RT [3] . Radiation-induced esophageal injury occurs more frequently when RT and chemotherapy are combined. Frequent concurrent chemotherapy may complicate identification of the clinical and dosimetric predictors of esophageal injury. RT regimens that escalate the dose or add chemotherapy lay stress on defining the clinical and dosimetric predictors of acute and late esophageal injury. Intensificaiton of additional regimens is not feasible without better dosimetric methods to limit dose-induced esophageal injury. Additional characteristics of the predictors of esophagitis must define the dose limits for radiation and quantify the effect of chemotherapy.
The clinical and dosimetric predictors of acute and late esophageal injury are not typically characterized. Severe esophageal injury has been reported in 46% incidence of acute grade 3-4 esophageal injuries [4] . It was reported that concurrent chemotherapy increases nearly 12-fold risk for esophageal injury [5] . Emami et al. [6] , reported that RT may lead to late stricture and/or perforation of the esophagus. Dillman et al. [7] , reported a similar incidence of esophageal injury (<1%). It was reported that late esophageal injury following aggressive, high-dose conformal RT is common but rarely severe; dosimetric variables addressing the longitudinal and circumferential characteristics of the esophagus have biologic rationale and are predictive of late injury [8] . Patel et al. [9] , found that concurrent chemotherapy and hyperfractionated RT after surgery in patients with NSCLC are significantly associated with acute grade 2 or worse esophageal injury. Werner-Wasik et al. [10] , reported that concurrent chemotherapy and twice-daily RT are associated with higher grades and longer durations of acute esophagitis. Concurrent chemotherapy combined with RT appears to have lower esophageal radiation tolerance, resulting in markedly higher incidence of esophagitis [11] . We found a significant association between concurrent chemotherapy and the development of higher grades of esophagitis. Contrary to the findings of Maguire et al. [8] , we did not find any significant association between the incidence of esophagitis and the the longitudinal and circumferential characteristics of the esophagus. However, Kiura et al. [12] , reported that concurrent thoracic radiation therapy and chemotherapy are effective and tolerable in patients with advanced NSCLC. Singh et al. [13] , found that concurrent chemotherapy is significantly associated with the risk of grade 3-5 esophageal injury in patients with NSCLC. Advances in the delivery of RT and target delineation along with development of radioprotectors, intensity-modulated RT may allow the delivery of high doses to thoracic tumors while minimizing the dose to adjacent normal structures such as the esophagus. The introduction of fluoro-deoxyglucose positron emission tomography scanning into traditional CT images for 3D treatment planning may improve target delineation, thus allowing reduced clinical target volumes with consequent reductions in the volume of irradiated esophagus. Marks et al. [14] , reported that, without a definitive threshold dose, a differential dose-volumehistogram (DVH) may be useful in predicting the outcome if the dose-response curve for regional organ dysfunction is known. Since the esophagus is a hollow tube, a dosesurface-histogram (DSH) might be a better descriptor than DVH. The relationship between the lumenal organ and the clinical/dosimetric factors is very difficult to investigate, thus both DVH and DSH are not ideal predictors of biologic outcome [8] . Yoshizawa et al. [15] , reported that carboplatin and 5-fluorouracil administered daily with concurrent thoracic radiation therapy in patients with NSCLC induce acceptable injury. Antonadou et al. [16] , found that amifostine, a radioprotector, reduces the incidence of pneumonitis and esophagitis without compromising the antitumor efficacy of radiation treatment in patients with 
